|
|
Volumn 24, Issue 1, 2006, Pages 3-4
|
|
Biotech jostles with pharma for slice of HIV market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMD 070;
AMD 887;
ANTIVIRUS AGENT;
APLAVIROC;
CD4 ANTIGEN;
CHEMOKINE RECEPTOR CCR5;
CHEMOKINE RECEPTOR CCR5 ANTAGONIST;
CHEMOKINE RECEPTOR CXCR4;
CHEMOKINE RECEPTOR CXCR4 ANTAGONIST;
ENFUVIRTIDE;
ENTRY INHIBITOR;
ETANERCEPT;
MARAVIROC;
MONOCLONAL ANTIBODY;
OKT 4;
PRO 140;
PROTEINASE INHIBITOR;
RNA;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
TNX 355;
UNCLASSIFIED DRUG;
VICRIVIROC;
BIOTECHNOLOGY;
CLINICAL TRIAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOCOMPETENT CELL;
INFECTION;
INJECTION SITE REACTION;
LIVER TOXICITY;
MUTATION;
NOTE;
PRIORITY JOURNAL;
QUALITY OF LIFE;
RHEUMATOID ARTHRITIS;
RNA REPLICATION;
UNSPECIFIED SIDE EFFECT;
VIRUS STRAIN;
ANTI-HIV AGENTS;
BIOTECHNOLOGY;
DRUG APPROVAL;
DRUG INDUSTRY;
ECONOMIC COMPETITION;
MARKETING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
HUMAN IMMUNODEFICIENCY VIRUS;
|
|
EID: 30544451858
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0106-3 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
